The 1st Psoriasis Symposium, organised by the Psoriasis Association of Bosnia and Herzegovina in collaboration with the Skin Inflammation & Psoriasis International Network (SPIN), the International Society of Dermatology and the European Academy of Dermatology and Venerology, was held in Sarajevo on 13-15 October 2017.
The Symposium was intended to provide delegates with the latest research and facts on diagnoses and genetics of psoriasis and psoriatic arthritis, long-term treatment with available therapies and treatments in development.
Approximately 200 participants and 40 guests from 22 countries across three continents participated in the Symposium.
The Symposium’s scientific programme included lectures by 26 international invited speakers, with the aim of presenting contemporary achievements in psoriasis and exchanging experiences.
There were 46 lectures and 21 poster presentations as well as 5 sponsored satellite symposia.
The main topics of the Symposium were:
- Immune system and psoriatic disease
- Psoriasis as a systemic disease
- Psoriasis in childhood and pregnancy
- Clinical and diagnostic characteristics of psoriasis and psoriatic arthritis
- Psoriasis therapy: from conventional therapies to biological drugs
- Free themes
As a partner organization, SPIN organized a session during this meeting.
Following the welcome and introductory speeches of SPIN Chair Professor Jo Lambert, lectures were held by the members of the SPIN Scientific Committee:
- Prof. Nejib Doss, Tunisia: Nail psoriasis: differential diagnosis
- Prof. Christopher Griffiths, UK: Systems medicine and psoriasis management
- Prof. Romana Ceovoc, Croatia: Topical treatments and phototherapy in the era of biologics
- Prof. Thomas A. Luger, Germany: Novel therapies for psoriasis: where are we going?
- Prof. Jo Lambert, Belgium: Tailored prescribing of biologicals: a challenge for the near future.
That event was also marked by the celebration of World Psoriasis Day - a day for awareness and advocacy for all people living with psoriasis and psoriatic arthritis around the world!
Rich cultural and social programs and the unique multicultural spirit and historical heritage of Sarajevo city have contributed to the good mood of all participants wishing to meet again and to exchange some new experiences.
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
- 2019/04/18 Focus on...
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Off-label studies on apremilast in dermatology: a review.
Maloney NJ et al.
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat.
2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)
see on pubmed
Our ambition in a changing landscape of psoriasis treatments.
van de Kerkhof PCM et al.
Our ambition in a changing landscape of psoriasis treatments.
J Dermatolog Treat.
2020 Mar , 31, (2):105-107.
CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes.
J. Cell. Physiol..
2020 Mar , 235, (3):1895-1902.
CARD14/CARMA2sh (CARMA2sh) is a scaffold protein whose mutations are associated with the onset of human genetic psoriasis and other inflammatory skin disorders. Here we show that the immunomodulatory adapter protein TRAF family member-associated NF-κB activator (TANK) forms a complex with CARMA2sh and MALT1 in a human keratinocytic cell line. We also show that CARMA2 and TANK are individually required to activate the nuclear factor κB (NF-κB) response following exposure to (...)
see on pubmed
on Atopic Dermatitis
Off-label studies on apremilast in dermatology: a review.
Maloney NJ et al.
Off-label studies on apremilast in dermatology: a review.
J Dermatolog Treat.
2020 Mar , 31, (2):131-140.
Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. The PubMed/MEDLINE and ClinicalTrials.gov databases were queried with the term 'apremilast,' with results manually screened to identify (...)
see on pubmed
Atopic dermatitis induces anxiety- and depressive-like behaviors with concomitant neuronal adaptations in brain reward circuits in mice.
Prog. Neuropsychopharmacol. Biol. Psychiatry.
2020 Mar 02, 98:109818.
Clinically, it has been reported that atopic dermatitis (AD) has been linked with negative emotional problems such as depression and anxiety, thereby reducing the quality of life, but little is known about the molecular mechanism that underlies AD-associated emotional impairments. We sought to determine whether AD could induce anxiety- and depressive-like symptoms in mice and to identify pertinent signaling changes in brain reward circuitry. AD-like lesions were induced by the repeated (...)
see on pubmed
Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial.
J Ethnopharmacol.
2020 Mar 25, 250:112477.
Indigo naturalis, a herbal medicine with a history of use dating back to ancient times, may be a good alternative topical treatment for atopic dermatitis (AD).
see on pubmed
